Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Employee Rating

3.7More
TypePublic
HQSan Francisco, US
Founded2015
Size (employees)125 (est)+3%
Websitedenalitherapeutics.com
Denali Therapeutics was founded in 2015 and is headquartered in San Francisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Denali Therapeutics

Ryan Watts

Ryan Watts

CEO
Alexander Schuth

Alexander Schuth

COO
Carole Ho

Carole Ho

Chief Medical Officer
Steve Krognes

Steve Krognes

CFO
Mark Dresser

Mark Dresser

Head of Development Sciences
Cindy Dunkle

Cindy Dunkle

Head of Human Resources
Show more

Denali Therapeutics Office Locations

Denali Therapeutics has an office in San Francisco
San Francisco, (HQ)
151 Oyster Point Blvd
Show all (1)
Report incorrect company information

Denali Therapeutics Financials and Metrics

Denali Therapeutics Revenue

USD

Net income (Q2, 2018)

(54.7m)

EBIT (Q2, 2018)

(57.4m)

Market capitalization (12-Dec-2018)

2.0b

Closing stock price (12-Dec-2018)

20.8

Cash (30-Jun-2018)

33.1m
Denali Therapeutics's current market capitalization is $2 b.
Annual
USDFY, 2015FY, 2016FY, 2017

Sales and marketing expense

5.1m11.7m15.7m

R&D expense

11.6m75.7m74.5m

Operating expense total

16.7m87.4m90.1m

EBIT

(16.7m)(87.4m)(90.1m)
Quarterly
USDQ1, 2018Q2, 2018

General and administrative expense

5.6m6.9m

R&D expense

20.8m52.1m

Operating expense total

26.4m59.0m

EBIT

(25.7m)(57.4m)
Annual
USDFY, 2016FY, 2017

Cash

39.9m218.4m

Prepaid Expenses

3.6m3.4m

Current Assets

182.0m409.6m

PP&E

15.3m14.9m
Quarterly
USDQ1, 2018Q2, 2018

Cash

44.0m33.1m

Current Assets

377.4m377.4m

PP&E

14.9m13.3m

Total Assets

614.0m572.1m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(16.8m)(86.7m)(88.2m)

Depreciation and Amortization

121.0k1.5m3.1m

Accounts Payable

1.7m161.0k207.0k

Cash From Operating Activities

(15.1m)(72.4m)(76.6m)
Quarterly
USDQ1, 2018Q2, 2018

Net Income

(23.7m)(78.4m)

Depreciation and Amortization

854.0k2.7m

Accounts Payable

(951.0k)7.1m

Cash From Operating Activities

33.6m(8.2m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Denali Therapeutics News and Updates

Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors

SOUTH SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2018, provided b…

Denali Therapeutics Reports Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2018.

Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson’s Disease

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 clinical study with DNL201, a sma…

VC-backed Denali Therapeutics goes public

South San Francisco-based Denali Therapeutics Inc, which is focused on developing treatments for patients with neurodegenerative diseases, has debuted its IPO after pricing its 13.8 million shares at $18 per share. The stock began trading December 8, 2017 on the NASDAQ under the ticker symbol "DNLI.…
Report incorrect company information

Denali Therapeutics Company Life and Culture

Report incorrect company information

Denali Therapeutics Frequently Asked Questions

  • When was Denali Therapeutics founded?

    Denali Therapeutics was founded in 2015.

  • Who are Denali Therapeutics key executives?

    Denali Therapeutics's key executives are Ryan Watts, Alexander Schuth and Carole Ho.

  • How many employees does Denali Therapeutics have?

    Denali Therapeutics has 125 employees.

  • Who are Denali Therapeutics competitors?

    Competitors of Denali Therapeutics include Agendia, Stealth BioTherapeutics and Orchard Therapeutics.

  • Where is Denali Therapeutics headquarters?

    Denali Therapeutics headquarters is located at 151 Oyster Point Blvd, San Francisco.

  • Where are Denali Therapeutics offices?

    Denali Therapeutics has an office in San Francisco.

  • How many offices does Denali Therapeutics have?

    Denali Therapeutics has 1 office.